What is Chardan Capital's Forecast for MNPR FY2025 Earnings?

Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) - Equities researchers at Chardan Capital issued their FY2025 earnings per share (EPS) estimates for shares of Monopar Therapeutics in a report issued on Tuesday, June 24th. Chardan Capital analyst K. Nakae expects that the company will earn ($2.02) per share for the year. Chardan Capital currently has a "Buy" rating and a $60.00 price objective on the stock. The consensus estimate for Monopar Therapeutics' current full-year earnings is ($1.65) per share. Chardan Capital also issued estimates for Monopar Therapeutics' FY2026 earnings at ($2.87) EPS.

Other analysts also recently issued research reports about the company. HC Wainwright reissued a "buy" rating and issued a $40.00 price objective on shares of Monopar Therapeutics in a research note on Tuesday, April 1st. Wall Street Zen upgraded shares of Monopar Therapeutics from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. Piper Sandler reissued an "overweight" rating and set a $76.00 price objective on shares of Monopar Therapeutics in a research note on Wednesday, March 19th. Finally, Jones Trading reaffirmed a "hold" rating on shares of Monopar Therapeutics in a research report on Wednesday, April 2nd. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $56.50.

Monopar Therapeutics Trading Up 4.2%

MNPR traded up $1.40 on Friday, reaching $34.96. The company had a trading volume of 54,564 shares, compared to its average volume of 359,289. The company has a market capitalization of $213.92 million, a P/E ratio of -10.04 and a beta of 1.01. The company has a fifty day moving average of $36.42 and a 200-day moving average of $34.97. Monopar Therapeutics has a one year low of $1.72 and a one year high of $54.30.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last posted its earnings results on Tuesday, May 13th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.27.

Hedge Funds Weigh In On Monopar Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in MNPR. Janus Henderson Group PLC acquired a new stake in shares of Monopar Therapeutics in the fourth quarter worth $23,435,000. Adage Capital Partners GP L.L.C. purchased a new stake in Monopar Therapeutics in the 4th quarter worth about $13,182,000. RA Capital Management L.P. acquired a new stake in Monopar Therapeutics during the 4th quarter worth about $11,247,000. Point72 Asset Management L.P. purchased a new position in Monopar Therapeutics during the 4th quarter valued at about $3,694,000. Finally, ADAR1 Capital Management LLC acquired a new position in shares of Monopar Therapeutics in the 4th quarter valued at about $2,861,000. 1.83% of the stock is currently owned by hedge funds and other institutional investors.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.